Dry Eye Disease Market
Jun 06, 2025
Upcoming Contenders in Dry Eye Disease Drug Space: 5 Therapies to Watch Post-TRYPTYR Approval
The recent approval of the dry eye disease drug TRYPTYR has heightened competition among pharmaceutical companies. Six years after spinning off from Novartis and going public, eye care company Alcon has secured its first FDA approval for a prescription medication targeting dry eye disease. The dry eye dise...
Read More...
Jun 02, 2025
Dry Eye Disease Treatment: A Growing Space with Expanding Therapeutic Options
Dry eye disease (DED) is a common yet often underestimated condition affecting millions worldwide. Characterized by insufficient tear production or poor tear quality, it leads to persistent eye discomfort, irritation, and vision problems. Studies suggest that up to 30% of the adult population may experience some de...
Read More...
Apr 08, 2025
Amgen’s UPLIZNA Wins First FDA Nod for IgG4-Related Disease; Aldeyra Gets FDA CRL for Reproxalap in Dry Eye; Novartis’ Vanrafia Snags Accelerated FDA OK for IgAN Proteinuria; Biogen’s BIIB080 Earns Fast Track for Alzheimer’s; Epicrispr’s EPI-321 Cleared by FDA for FSHD
Amgen’s UPLIZNA Becomes First FDA-Approved Treatment for IgG4-Related Disease Amgen announced that the FDA has approved UPLIZNA (inebilizumab-cdon) as the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD), a rare and chronic immune-mediated inflammatory condition that can affec...
Read More...
Dec 20, 2023
Exploring the Growing Demand and Evolving Market Dynamics of Artificial Tears
The landscape of technology has indelibly reshaped various industries, and the healthcare sector stands as a prime beneficiary, especially evident in the profound innovation and intense development seen in the Artificial Tears Market in recent years. The advancements in nanotechnology, biotechnology, and material s...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
